Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation
Authors:
- David R. JonesDJDavid R. Jones
- Andrea R. MastersAMAndrea R. Masters
- Cong XuCXCong Xu
- Yingying GuoYGYingying Guo
- Zeruesenay DestaZDZeruesenay Desta
- 1 July 2010
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 38 (7) , 1218-1229
Abstract
Efavirenz primary and secondary metabolism was investigated in vitro and in vivo. In human liver microsome (HLM) samples, 7- and 8-hydroxyefavirenz accounted for 22.5 and 77.5% of the overall efavirenz metabolism, respectively. Kinetic, inhibition, and correlation analyses in HLM samples and experiments in expressed cytochrome P450 show that CYP2A6 is the principal catalyst of efavirenz 7-hydroxylation. Although CYP2B6 was the main enzyme catalyzing efavirenz 8-hydroxylation, CYP2A6 also seems to contribute. Both 7- and 8-hydroxyefavirenz were further oxidized to novel dihydroxylated metabolite(s) primarily by CYP2B6. These dihydroxylated metabolite(s) were not the same as 8,14-dihydroxyefavirenz, a metabolite that has been suggested to be directly formed via 14-hydroxylation of 8-hydroxyefavirenz, because 8,14-dihydroxyefavirenz was not detected in vitro when efavirenz, 7-, or 8-hydroxyefavirenz were used as substrates. Efavirenz and its primary and secondary metabolites that were identified in vitro were quantified in plasma samples obtained from subjects taking a single 600-mg oral dose of efavirenz. 8,14-Dihydroxyefavirenz was detected and quantified in these plasma samples, suggesting that the glucuronide or the sulfate of 8-hydroxyefavirenz might undergo 14-hydroxylation in vivo. In conclusion, efavirenz metabolism is complex, involving unique and novel secondary metabolism. Although efavirenz 8-hydroxylation by CYP2B6 remains the major clearance mechanism of efavirenz, CYP2A6-mediated 7-hydroxylation (and to some extent 8-hydroxylation) may also contribute. Efavirenz may be a valuable dual phenotyping tool to study CYP2B6 and CYP2A6, and this should be further tested in vivo.Keywords
This publication has 37 references indexed in Scilit:
- PolymorphicCYP2B6: Molecular Mechanisms and Emerging Clinical SignificancePharmacogenomics, 2007
- Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populationsClinical Pharmacology & Therapeutics, 2006
- Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.2004
- Metabolism of N,N′,N″-Triethylenethiophosphoramide by CYP2B1 and CYP2B6 Results in the Inactivation of Both Isoforms by Two Distinct MechanismsThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimensBiochemical and Biophysical Research Communications, 2004
- SELECTIVE INHIBITION OF CYP2B6-CATALYZED BUPROPION HYDROXYLATION IN HUMAN LIVER MICROSOMES IN VITRODrug Metabolism and Disposition, 2004
- Liquid Chromatography/Mass Spectrometry and High-Field Nuclear Magnetic Resonance Characterization of Novel Mixed Diconjugates of the Non-nucleoside Human Immunodeficiency Virus-1 Reverse Transcriptase Inhibitor, EfavirenzDrug Metabolism and Disposition, 1999
- THE ROLE OF CYP2B6 IN HUMAN XENOBIOTIC METABOLISM*Drug Metabolism Reviews, 1999
- Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.The Journal of Pharmacology and Experimental Therapeutics, 1996
- Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.Drug Metabolism and Disposition, 1995